Cell permeability beyond the rule of 5

Advanced Drug Delivery Reviews

Volumn 101, Issue , 2016, Pages 42-61

  Matsson, Pär ^a   Doak, Bradley C ^b   Over, Björn ^c   Kihlberg, Jan ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b MONASH UNIVERSITY   (Australia)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

Beyond the rule of 5; Conformational shielding; Cyclic peptides; Efflux transporters; Intramolecular hydrogen bonds; Macrocycles; Permeability; Quantitative structure permeability relationships

Indexed keywords

ALKYLATION; BINDING SITES; CELLS; COMPLEXATION; CYTOLOGY; DRUG PRODUCTS; MECHANICAL PERMEABILITY; PEPTIDES; SHIELDING; SOLUBILITY;

BEYOND THE RULE OF 5; CYCLIC PEPTIDES; EFFLUX TRANSPORTER; INTRA-MOLECULAR HYDROGEN BONDS; MACROCYCLES; QUANTITATIVE STRUCTURES;

HYDROGEN BONDS;

ABC TRANSPORTER; ASCOMYCIN; ATAZANAVIR; AZITHROMYCIN; BEYOND THE RULE OF FIVE COMPOUND; CLARITHROMYCIN; CYCLOSPORIN A; DACLATASVIR; DIGOXIN; DRUG; ERYTHROMYCIN; EVEROLIMUS; ITRACONAZOLE; ORTATAXEL; OUABAIN; PACLITAXEL; RAPAMYCIN; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; RITONAVIR; SIMEPREVIR; SPIRAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG; ZOTAROLIMUS;

CELL MEMBRANE PERMEABILITY; CONFORMATION; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG UPTAKE; FIRST PASS EFFECT; HUMAN; HYDROGEN BOND; INTESTINE ABSORPTION; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; CHEMISTRY; ORAL DRUG ADMINISTRATION; SOLUBILITY;

ADMINISTRATION, ORAL; CELL MEMBRANE PERMEABILITY; HUMANS; HYDROGEN BONDING; INTESTINAL ABSORPTION; PHARMACEUTICAL PREPARATIONS; SOLUBILITY;

EID: 84964799737     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2016.03.013     Document Type: Review

References (166)

1. [1] Bunnage, M.E., Getting pharmaceutical R&D back on track. Nat. Chem. Biol. 7 (2011), 335–339.
2. [2] Scannell, J.W., Blanckley, A., Boldon, H., Warrington, B., Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 11 (2012), 191–200.
3. [3] Doak, B.C., Zheng, J., Dobritzsch, D., Kihlberg, J., How beyond rule of 5 drugs and clinical candidates bind to their targets. J. Med. Chem. 59 (2016), 2312–2327.
4. [4] Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J., Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23 (1997), 3–25.
5. [5] Gleeson, M.P., Generation of a set of simple, interpretable ADMET rules of thumb. J. Med. Chem. 51 (2008), 817–834.
6. [6] Guimaraes, C.R.W., Mathiowetz, A.M., Shalaeva, M., Goetz, G., Liras, S., Use of 3D properties to characterize beyond rule-of-5 property space for passive permeation. J. Chem. Inf. Model. 52 (2012), 882–890.
7. [7] Yang, Y., Engkvist, O., Llinas, A., Chen, H., Beyond size, ionization state, and lipophilicity: influence of molecular topology on absorption, distribution, metabolism, excretion, and toxicity for druglike compounds. J. Med. Chem. 55 (2012), 3667–3677.
8. [8] Meanwell, N.A., Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. Chem. Res. Toxicol. 24 (2011), 1420–1456.
9. [9] Palm, K., Stenberg, P., Luthman, K., Artursson, P., Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm. Res. 14 (1997), 568–571.
10. [10] Veber, D.F., Johnson, S.R., Cheng, H.Y., Smith, B.R., Ward, K.W., Kopple, K.D., Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 45 (2002), 2615–2623.
11. [11] Artursson, P., Palm, K., Luthman, K., Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv. Drug Deliv. Rev. 22 (1996), 67–84.
12. [12] Irvine, J.D., Takahashi, L., Lockhart, K., Cheong, J., Tolan, J.W., Selick, H.E., Grove, J.R., MDCK (Madin–Darby canine kidney) cells: a tool for membrane permeability screening. J. Pharm. Sci. 88 (1999), 28–33.
13. [13] White, T.R., Renzelman, C.M., Rand, A.C., Rezai, T., McEwen, C.M., Gelev, V.M., Turner, R.A., Linington, R.G., Leung, S.S.F., Kalgutkar, A.S., Bauman, J.N., Zhang, Y., Liras, S., Price, D.A., Mathiowetz, A.M., Jacobsen, M.P., Lokey, R.S., On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffolds. Nat. Chem. Biol. 7 (2011), 810–817.
14. [14] Kansy, M., Senner, F., Gubernator, K., Physicochemical high throughput screening: Parallel artificial membrane permeation assay in the description of passive absorption processes. J. Med. Chem. 41 (1998), 1007–1010.
15. [15] Hopkins, A.L., Keseru, G.M., Leeson, P.D., Rees, D.C., Reynolds, C.H., The role of ligand efficiency metrics in drug discovery. Nat. Rev. Drug Discov. 13 (2014), 105–121.
16. [16] Abad-Zapatero, C., A sorcerer's apprentice and the rule of five: from rule-of-thumb to commandment and beyond. Drug Discov. Today 12 (2007), 995–997.
17. [17] Bennani, Y.L., Drug discovery in the next decade: innovation needed ASAP. Drug Discov. Today 16 (2011), 779–792.
18. [18] Walters, W.P., Going further than Lipinski's rule in drug design. Expert Opin. Drug Discovery 7 (2012), 99–107.
19. [19] Zhang, M.Q., Wilkinson, B., Drug discovery beyond the ‘rule-of-five’. Curr. Opin. Biotechnol. 18 (2007), 478–488.
20. [20] Kenny, P.W., Leitao, A., Montanari, C.A., Ligand efficiency metrics considered harmful. J. Comput. Aided Mol. Des. 28 (2014), 699–710.
21. [21] Bickerton, G.R., Paolini, G.V., Besnard, J., Muresan, S., Hopkins, A.L., Quantifying the chemical beauty of drugs. Nat. Chem. 4 (2012), 90–98.
22. [22] Egan, W.J., Merz, K.M. Jr., Baldwin, J.J., Prediction of drug absorption using multivariate statistics. J. Med. Chem. 43 (2000), 3867–3877.
23. [23] Johnson, T.W., Dress, K.R., Edwards, M., Using the golden triangle to optimize clearance and oral absorption. Bioorg. Med. Chem. Lett. 19 (2009), 5560–5564.
24. [24] Ritchie, T.J., Ertl, P., Lewis, R., The graphical representation of ADME-related molecule properties for medicinal chemists. Drug Discov. Today 16 (2011), 65–72.
25. [25] Waring, M.J., Lipophilicity in drug discovery. Expert Opin. Drug Discovery 5 (2010), 235–248.
26. [26] Leeson, P.D., Springthorpe, B., The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Discov. 6 (2007), 881–890.
27. [27] Doak, B.C., Over, B., Giordanetto, F., Kihlberg, J., Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates. Chem. Biol. 21 (2014), 1115–1142.
28. [28] Hann, M.M., Molecular obesity, potency and other addictions in drug discovery. Med. Chem. Commun. 2 (2011), 349–355.
29. [29] Vieth, M., Sutherland, J.J., Dependence of molecular properties on proteomic family for marketed oral drugs. J. Med. Chem. 49 (2006), 3451–3453.
30. [30] Paolini, G.V., Shapland, R.H.B., van Hoorn, W.P., Mason, J.S., Hopkins, A.L., Global mapping of pharmacological space. Nat. Biotechnol. 24 (2006), 805–815.
31. [31] Morphy, R., The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds. J. Med. Chem. 49 (2006), 2969–2978.
32. [32] Hopkins, A.L., Groom, C.R., The druggable genome. Nat. Rev. Drug Discov. 1 (2002), 727–730.
33. [33] Rask-Andersen, M., Masuram, S., Schioth, H.B., The druggable genome: evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication. Annu. Rev. Pharmacol. Toxicol. 54 (2014), 9–26.
34. [34] Surade, S., Blundell, T.L., Structural biology and drug discovery of difficult targets: the limits of ligandability. Chem. Biol. 19 (2012), 42–50.
35. [35] Perola, E., Herman, L., Weiss, J., Development of a rule-based method for the assessment of protein druggability. J. Chem. Inf. Model. 52 (2012), 1027–1038.
36. [36] Giordanetto, F., Kihlberg, J., Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties?. J. Med. Chem. 57 (2014), 278–295.
37. [37] Villar, E.A., Beglov, D., Chennamadhavuni, S., Porco, J.A., Kozakov, D., Vajda, S., Whitty, A., How proteins bind macrocycles. Nat. Chem. Biol. 10 (2014), 723–732.
38. [38] Arkin, M.R., Tang, Y., Wells, J.A., Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. Chem. Biol. 21 (2014), 1102–1114.
39. [39] Artursson, P., Karlsson, J., Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun. 175 (1991), 880–885.
40. [40] Over, B., Matsson, P., Tyrchan, C., Artursson, P., Doak, B.C., Foley, M.A., Hilgendorf, C., Johnston, S., Lee, M.D., Lewis, R., McCarren, P., Muncipinto, G., Perry, U. Norinder, M.W.D., Duvall, J.R., Kihlberg, J., Understanding macrocycle cell permeability. 2015 (Submitted manuscript).
41. [41] Marchi, E., Montecchi, L., Venturini, A.P., Mascellan, G., Brufani, M., Cellai, L., 4-Deoxypyrido[1′,2′:1,2]imidazo[5,4-c]rifamycin SV derivatives. A new series of semisynthetic rifamycins with high antibacterial activity and low gastroenteric absorption. J. Med. Chem. 28 (1985), 960–963.
42. [42] Brufani, M., Cellai, L., Cerrini, S., Fedeli, W., Marchi, E., Segre, A., Vaciago, A., X-ray crystal structure of 4-deoxy-3′-bromopyrido[1′,2′-1,2]imidazo[5,4-c]rifamycin SV. J. Antibiot. 37 (1984), 1623–1627.
43. [43] Rand, A.C., Leung, S.S.F., Eng, H., Rotter, C.J., Sharma, R., Kalgutkar, A.S., Zhang, Y., Varma, M.V., Farley, K.A., Khunte, B., Limberakis, C., Price, D.A., Liras, S., Mathiowetz, A.M., Jacobson, M.P., Lokey, R.S., Optimizing PK properties of cyclic peptides: the effect of side chain substitutions on permeability and clearance. Med. Chem. Commun. 3 (2012), 1282–1289.
44. [44] Over, B., McCarren, P., Artursson, P., Foley, M., Giordanetto, F., Grönberg, G., Hilgendorf, C., Lee, M.D., Matsson, P., Muncipinto, G., Pellisson, M., Perry, M.W.D., Svensson, R., Duvall, J.D., Kihlberg, J., Impact of stereospecific intramolecular hydrogen bonding on cell permeability and physicochemical properties. J. Med. Chem. 57 (2014), 2746–2754.
45. [45] Rezai, T., Yu, B., Millhauser, G.L., Jacobson, M.P., Lokey, R.S., Testing the conformational hypothesis of passive membrane permeability using synthetic cyclic peptide diastereomers. J. Am. Chem. Soc. 128 (2006), 2510–2511.
46. [46] Rezai, T., Bock, J.E., Zhou, M.V., Kalyanaraman, C., Lokey, R.S., Jacobsen, M.P., Conformational flexibility, internal hydrogen bonding, and passive membrane permeability: successful in silico prediction of the relative permeabilities of cyclic peptides. J. Am. Chem. Soc. 128 (2006), 14073–14080.
47. [47] Hewitt, W.M., Leung, S.S.F., Pye, C.R., Ponkey, A.R., Bednarek, M., Jacobson, M.P., Lokey, R.S., Cell-permeable cyclic peptides from synthetic libraries inspired by natural products. J. Am. Chem. Soc. 137 (2015), 715–721.
48. [48] Hill, T.A., Lohman, R.-J., Hoang, H.N., Nielsen, D.S., Scully, C.C.G., Kok, W.M., Liu, L., Lucke, A.J., Stoermer, M.J., Schroeder, C.I., Chaousis, S., Colless, B., Bernhardt, P.V., Edmonds, D.J., Griffith, D.A., Rotter, C.J., Ruggeri, R.B., Price, D.A., Liras, S., Craik, D.J., Fairlie, D.P., Cyclic penta- and hexaleucine peptides without N-methylation are orally absorbed. ACS Med. Chem. Lett. 5 (2014), 1148–1151.
49. [49] Nielsen, D.S., Hoang, H.N., Lohman, R.-J., Hill, T.A., Lucke, A.J., Craik, D.J., Edmonds, D.J., Griffith, D.A., Rotter, C.J., Ruggeri, R.B., Price, D.A., Liras, S., Fairlie, D.P., Improving on nature: making a cyclic heptapeptide orally bioavailable. Angew. Chem. Int. Ed. 53 (2014), 12059–12063.
50. [50] Wang, C.K., Northfield, S.E., Colless, B., Chaousis, S., Hamernig, I., Lohman, R.-J., Nielsen, D.S., Schroeder, C.I., Liras, S., Price, D.A., Fairlie, D.P., Craik, D.J., Rational design and synthesis of an orally bioavailable peptide guided by NMR amide temperature coefficients. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 17504–17509.
51. [51] Wang, C.K., Northfield, S.E., Swedberg, J.E., Colless, B., Chaousis, S., Price, D.A., Liras, S., Craik, D.J., Exploring experimental and computational markers of cyclic peptides: charting islands of permeability. Eur. J. Med. Chem. 97 (2015), 202–213.
52. [52] Bockus, A.T., Lexa, K.W., Pye, C.R., Kalgutkar, A.S., Gardner, J.W., Hund, K.C.R., Hewitt, W.M., Schwochert, J.A., Glassey, E., Price, D.A., Mathiowetz, A.M., Liras, S., Jacobson, M.P., Lokey, R.S., Probing the physicochemical boundaries of cell permeability and oral bioavailability in lipophilic macrocycles inspired by natural products. J. Med. Chem. 58 (2015), 4581–4589.
53. [53] Bockus, A.T., Schwochert, J.A., Pye, C.R., Townsend, C.E., Sok, V., Bednarek, M.A., Lokey, R.S., Going out on a limb: delineating the effects of β-branching, N-methylation, and side chain size on the passive permeability, solubility, and flexibility of sanguinamide A analogues. J. Med. Chem. 58 (2015), 7409–7418.
54. [54] Thansandote, P., Harris, R.M., Dexter, H.L., Simpson, G.L., Pal, S., Upton, R.J., Valko, K., Improving the passive permeability of macrocyclic peptides: balancing permeability with other physicochemical properties. Bioorg. Med. Chem. 23 (2015), 322–327.
55. [55] Marelli, U.K., Bezençon, J., Puig, E., Ernst, B., Kessler, H., Enantiomeric cyclic peptides with different Caco-2 permeability suggest carrier-mediated transport. Chem. Eur. J. 21 (2015), 8023–8027.
56. [56] Beck, J.G., Chatterjee, J., Laufer, B., Kiran, M.U., Frank, A.O., Neubauer, S., Ovadia, O., Greenberg, S., Gilon, C., Hoffman, A., Kessler, H., Intestinal permeability of cyclic peptides: common key backbone motifs identified. J. Am. Chem. Soc. 134 (2012), 12125–12133.
57. [57] Biron, E., Chatterjee, J., Ovadia, O., Langenegger, D., Brueggen, J., Hoyer, D., Schmid, H.A., Jelinek, R., Gilon, C., Hoffman, A., Kessler, H., Improving oral bioavailability of peptides by multiple N-methylation: somatostatin analogues. Angew. Chem. Int. Ed. 47 (2008), 2595–2599.
58. [58] Bockus, A.T., McEwen, C.M., Lokey, R.S., Form and function in cyclic peptide natural products: a pharmacokinetic perspective. Curr. Top. Med. Chem. 13 (2013), 821–836.
59. [59] Ahlbach, C.L., Lexa, K.W., Bockus, A.T., Chen, V., Crews, P., Jacobson, M.P., Lokey, R.S., Beyond cyclosporine A: conformation-dependent passive membrane permeabilities of cyclic peptide natural products. Future Med. Chem. 7 (2015), 2121–2130.
60. [60] Alex, A., Millan, D.S., Perez, M., Wakenhut, F., Whitlock, G.A., Intramolecular hydrogen bonding to improve membrane permeability and absorption in beyond rule of five chemical space. Med. Chem. Commun. 2 (2011), 669–674.
61. [61] Rafi, S.B., Hearn, B.R., Vedantham, P., Jacobson, M.P., Renslo, A.R., Predicting and improving the membrane permeability of peptidic small molecules. J. Med. Chem. 55 (2011), 3163–3169.
62. [62] Wakenhut, F., Tran, T.D., Pickford, C., Shaw, S., Westby, M., Smith-Burchnell, C., Watson, L., Paradowski, M., Milbank, J., Stonehouse, D., Cheung, K., Wybrow, R., Daverio, F., Crook, S., Statham, K., Leese, D., Stead, D., Adam, F., Hay, D., Roberts, L.R., Chiva, J.-Y., Nichols, C., Blakemore, D.C., Goetz, G.H., Che, Y., Gardner, I., Dayal, S., Pike, A., Webster, R., Pryde, D.C., The discovery of potent nonstructural protein 5A (NS5A) inhibitors with a unique resistance profile-part 2. ChemMedChem 9 (2014), 1387–1396.
63. [63] Shalaeva, M., Caron, G., Abramov, Y.A., O'Connell, T.N., Plummer, M.S., Yalamanchi, G., Farley, K.A., Goetz, G.H., Philippe, L., Shapiro, M.J., Integrating intramolecular hydrogen bonding (IMHB) considerations in drug discovery using ΔlogP as a tool. J. Med. Chem. 56 (2013), 4870–4879.
64. [64] Goetz, G.H., Farrell, W., Shalaeva, M., Sciabola, S., Anderson, D.P., Yan, J., Philippe, L., Shapiro, M.J., A high throughput method for the indirect detection of intramolecular hydrogen bonding. J. Med. Chem. 57 (2014), 2920–2929.
65. [65] Kuhn, B., Mohr, P., Stahl, M., Intramolecular hydrogen bonding in medicinal chemistry. J. Med. Chem. 53 (2010), 2601–2611.
66. [66] Driggers, E.M., Hale, S.P., Lee, J., Terrett, N.F., The exploration of macrocycles for drug discovery — an underexploited structural class. Nat. Rev. Drug Discov. 7 (2008), 608–624.
67. [67] Brandt, W., Haupt, V.J., Wessjohann, L.A., Chemoinformatic analysis of biologically active macrocycles. Curr. Top. Med. Chem. 10 (2010), 1361–1379.
68. [68] Mallinson, J., Collins, I., Macrocycles in new drug discovery. Future Med. Chem. 4 (2012), 1409–1438.
69. [69] Bogdan, A.R., Davies, N.L., James, K., Comparison of diffusion coefficients for matched pairs of macrocyclic and linear molecules over a drug-like molecular weight range. Org. Biomol. Chem. 9 (2011), 7727–7733.
70. [70] Okumu, F.W., Pauletti, G.M., Vander Velde, D.G., Siahaan, T.J., Borchardt, R.T., Effect of restricted conformational flexibility on the permeation of model hexapeptides across Caco-2 cell monolayers. Pharm. Res. 14 (1997), 169–175.
71. [71] Steinbeck, C., Hoppe, C., Kuhn, S., Floris, M., Guha, R., Willighagen, E.L., Recent developments of the chemistry development kit (CDK) — an open-source java library for chemo- and bioinformatics. Curr. Pharm. Des. 12 (2006), 2111–2120.
72. [72] Mathiowetz, A.M., Leung, S.S., Jacobson, M.P., Optimizing the permeability and oral bioavailability of macrocycles. Macrocycles in Drug Discovery, 2014, 367.
73. [73] Palm, K., Luthman, K., Ungell, A.L., Strandlund, G., Artursson, P., Correlation of drug absorption with molecular surface properties. J. Pharm. Sci. 85 (1996), 32–39.
74. [74] van De Waterbeemd, H., Camenisch, G., Folkers, G., Raevsky, O.A., Estimation of Caco‐2 cell permeability using calculated molecular descriptors. Quant. Struct.-Act. Relat. 15 (1996), 480–490.
75. [75] Castillo‐Garit, J.A., Marrero‐Ponce, Y., Torrens, F., García‐Domenech, R., Estimation of ADME properties in drug discovery: predicting Caco‐2 cell permeability using atom‐based stochastic and non‐stochastic linear indices. J. Pharm. Sci. 97 (2008), 1946–1976.
76. [76] Nordqvist, A., Nilsson, J., Lindmark, T., Eriksson, A., Garberg, P., Kihlén, M., A general model for prediction of Caco‐2 cell permeability. QSAR Comb. Sci. 23 (2004), 303–310.
77. [77] Egan, W.J., Lauri, G., Prediction of intestinal permeability. Adv. Drug Deliv. Rev. 54 (2002), 273–289.
78. [78] Young, R.C., Mitchell, R.C., Brown, T.H., Ganellin, C.R., Griffiths, R., Jones, M., Rana, K.K., Saunders, D., Smith, I.R., Sore, N.E., et al. Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists. J. Med. Chem. 31 (1988), 656–671.
79. [79] Leung, S.S., Mijalkovic, J., Borrelli, K., Jacobson, M.P., Testing physical models of passive membrane permeation. J. Chem. Inf. Model. 52 (2012), 1621–1636.
80. [80] Bemporad, D., Essex, J.W., Luttmann, C., Permeation of small molecules through a lipid bilayer: a computer simulation study. J. Phys. Chem. B 108 (2004), 4875–4884.
81. [81] Jacobson, M.P., Pincus, D.L., Rapp, C.S., Day, T.J., Honig, B., Shaw, D.E., Friesner, R.A., A hierarchical approach to all‐atom protein loop prediction. Proteins 55 (2004), 351–367.
82. [82] Swift, R.V., Amaro, R.E., Back to the future: can physical models of passive membrane permeability help reduce drug candidate attrition and move us beyond QSPR?. Chem. Biol. Drug Des. 81 (2013), 61–71.
83. [83] Cesar-Razquin, A., Snijder, B., Frappier-Brinton, T., Isserlin, R., Gyimesi, G., Bai, X., Reithmeier, R.A., Hepworth, D., Hediger, M.A., Edwards, A.M., Superti-Furga, G., A call for systematic research on solute carriers. Cell 162 (2015), 478–487.
84. [84] Giacomini, K., Huang, S., Tweedie, D., Benet, L., Brouwer, K., Chu, X., Dahlin, A., Evers, R., Fischer, V., Hillgren, K., Hoffmaster, K., Ishikawa, T., Keppler, D., Kim, R., Lee, C., Niemi, M., Polli, J., Sugiyama, Y., Swaan, P., Ware, J., Wright, S., Yee, S., Zamek-Gliszczynski, M., Zhang, L., Membrane transporters in drug development. Nat. Rev. Drug Discov. 9 (2010), 215–236.
85. [85] Hediger, M., Clemencon, B., Burrier, R., Bruford, E., The ABCs of membrane transporters in health and disease (SLC series): introduction. Mol. Asp. Med. 34 (2013), 95–107.
86. [86] Hillgren, K., Keppler, D., Zur, A., Giacomini, K., Stieger, B., Cass, C., Zhang, L., Emerging transporters of clinical importance: an update from the international transporter consortium. Clin. Pharmacol. Ther. 94 (2013), 52–63.
87. [87] Vasiliou, V., Vasiliou, K., Nebert, D.W., Human ATP-binding cassette (ABC) transporter family. Hum. Genomics 3 (2009), 281–290.
88. [88] Lin, L., Yee, S.W., Kim, R.B., Giacomini, K.M., SLC transporters as therapeutic targets: emerging opportunities. Nat. Rev. Drug Discov. 14 (2015), 543–560.
89. [89] Schlessinger, A., Matsson, P., Shima, J., Pieper, U., Yee, S., Kelly, L., Apeltsin, L., Stroud, R., Ferrin, T., Giacomini, K., Sali, A., Comparison of human solute carriers. Protein Sci. 19 (2010), 412–428.
90. [90] Dobson, P.D., Kell, D.B., Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule?. Nat. Rev. Drug Discov. 7 (2008), 205–220.
91. [91] Di, L., Artursson, P., Avdeef, A., Ecker, G.F., Faller, B., Fischer, H., Houston, J.B., Kansy, M., Kerns, E.H., Kramer, S.D., Lennernas, H., Sugano, K., Evidence-based approach to assess passive diffusion and carrier-mediated drug transport. Drug Discov. Today 17 (2012), 905–912.
92. [92] Sugano, K., Kansy, M., Artursson, P., Avdeef, A., Bendels, S., Di, L., Ecker, G.F., Faller, B., Fischer, H., Gerebtzoff, G., Lennernaes, H., Senner, F., Coexistence of passive and carrier-mediated processes in drug transport. Nat. Rev. Drug Discov. 9 (2010), 597–614.
93. [93] Matsson, P., Fenu, L.A., Lundquist, P., Wisniewski, J.R., Kansy, M., Artursson, P., Quantifying the impact of transporters on cellular drug permeability. Trends Pharmacol. Sci. 36 (2015), 255–262.
94. [94] Wu, C.Y., Benet, L.Z., Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 22 (2005), 11–23.
95. [95] Desai, P.V., Sawada, G.A., Watson, I.A., Raub, T.J., Integration of in silico and in vitro tools for scaffold optimization during drug discovery: predicting P-glycoprotein efflux. Mol. Pharm. 10 (2013), 1249–1261.
96. [96] Matsson, P., Artursson, P., Computational prospecting for drug-transporter interactions. Clin. Pharmacol. Ther. 94 (2013), 30–32.
97. [97] Matsson, P., Bergstrom, C., Computational modeling to predict the functions and impact of drug transporters. Silico Pharmacol., 3, 2015, 8.
98. [98] Mak, L., Marcus, D., Howlett, A., Yarova, G., Duchateau, G., Klaffke, W., Bender, A., Glen, R.C., Metrabase: a cheminformatics and bioinformatics database for small molecule transporter data analysis and (Q)SAR modeling. J. Cheminformatics, 7, 2015, 31.
99. [99] Zdrazil, B., Pinto, M., Vasanthanathan, P., Williams, A.J., Balderud, L.Z., Engkvist, O., Chichester, C., Hersey, A., Overington, J.P., Ecker, G.F., Annotating human P-glycoprotein bioassay data. Mol. Inf. 31 (2012), 599–609.
100. [100] Ozawa, N., Shimizu, T., Morita, R., Yokono, Y., Ochiai, T., Munesada, K., Ohashi, A., Aida, Y., Hama, Y., Taki, K., Maeda, K., Kusuhara, H., Sugiyama, Y., Transporter database, TP-Search: a web-accessible comprehensive database for research in pharmacokinetics of drugs. Pharm. Res. 21 (2004), 2133–2134.
101. [101] Sedykh, A., Fourches, D., Duan, J., Hucke, O., Garneau, M., Zhu, H., Bonneau, P., Tropsha, A., Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm. Res. 30 (2013), 996–1007.
102. [102] Wishart, D.S., Knox, C., Guo, A.C., Shrivastava, S., Hassanali, M., Stothard, P., Chang, Z., Woolsey, J., DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 34 (2006), D668–D672.
103. [103] Aller, S.G., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., Harrell, P.M., Trinh, Y.T., Zhang, Q., Urbatsch, I.L., Chang, G., Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science (New York, N.Y.) 323 (2009), 1718–1722.
104. [104] Ward, A.B., Szewczyk, P., Grimard, V., Lee, C.W., Martinez, L., Doshi, R., Caya, A., Villaluz, M., Pardon, E., Cregger, C., Swartz, D.J., Falson, P.G., Urbatsch, I.L., Govaerts, C., Steyaert, J., Chang, G., Structures of P-glycoprotein reveal its conformational flexibility and an epitope on the nucleotide-binding domain. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 13386–13391.
105. [105] Deng, D., Xu, C., Sun, P., Wu, J., Yan, C., Hu, M., Yan, N., Crystal structure of the human glucose transporter GLUT1. Nature 510 (2014), 121–125.
106. [106] Gottesman, M.M., Ambudkar, S.V., Xia, D., Structure of a multidrug transporter. Nat. Biotechnol. 27 (2009), 546–547.
107. [107] Singh, S.K., Piscitelli, C.L., Yamashita, A., Gouaux, E., A competitive inhibitor traps LeuT in an open-to-out conformation. Science (New York, N.Y.) 322 (2008), 1655–1661.
108. [108] Jiang, Y., Andrews, S.W., Condroski, K.R., Buckman, B., Serebryany, V., Wenglowsky, S., Kennedy, A.L., Madduru, M.R., Wang, B., Lyon, M., Doherty, G.A., Woodard, B.T., Lemieux, C., Do, M.G., Zhang, H., Ballard, J., Vigers, G., Brandhuber, B.J., Stengel, P., Josey, J.A., Beigelman, L., Blatt, L., Seiwert, S.D., Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease. J. Med. Chem. 57 (2014), 1753–1769.
109. [109] Ramsden, D., Tweedie, D.J., Chan, T.S., Taub, M.E., Li, Y., Bridging in vitro and in vivo metabolism and transport of faldaprevir in human using a novel cocultured human hepatocyte system, HepatoPac. Drug Metab. Dispos. 42 (2014), 394–406.
110. [110] Summa, V., Ludmerer, S.W., McCauley, J.A., Fandozzi, C., Burlein, C., Claudio, G., Coleman, P.J., DiMuzio, J.M., Ferrara, M., Di Filippo, M., Gates, A.T., Graham, D.J., Harper, S., Hazuda, D.J., McHale, C., Monteagudo, E., Pucci, V., Rowley, M., Rudd, M.T., Soriano, A., Stahlhut, M.W., Vacca, J.P., Olsen, D.B., Liverton, N.J., Carroll, S.S., MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob. Agents Chemother. 56 (2012), 4161–4167.
111. [111] Franke, R.M., Baker, S.D., Mathijssen, R.H., Schuetz, E.G., Sparreboom, A., Influence of solute carriers on the pharmacokinetics of CYP3A4 probes. Clin. Pharmacol. Ther. 84 (2008), 704–709.
112. [112] Garver, E., Hugger, E.D., Shearn, S.P., Rao, A., Dawson, P.A., Davis, C.B., Han, C., Involvement of intestinal uptake transporters in the absorption of azithromycin and clarithromycin in the rat. Drug Metab. Dispos. 36 (2008), 2492–2498.
113. [113] Lan, T., Rao, A., Haywood, J., Davis, C.B., Han, C., Garver, E., Dawson, P.A., Interaction of macrolide antibiotics with intestinally expressed human and rat organic anion-transporting polypeptides. Drug Metab. Dispos. 37 (2009), 2375–2382.
114. [114] Williamson, B., Dooley, K.E., Zhang, Y., Back, D.J., Owen, A., Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine. Antimicrob. Agents Chemother. 57 (2013), 6366–6369.
115. [115] Munic, V., Kelneric, Z., Mikac, L., Haber, V.E., Differences in assessment of macrolide interaction with human MDR1 (ABCB1, P-gp) using rhodamine-123 efflux, ATPase activity and cellular accumulation assays. Eur. J. Pharm. Sci. 41 (2010), 86–95.
116. [116] Nozinic, D., Milic, A., Mikac, L., Ralic, J., Padovan, J., Antolovic, R., Assessment of macrolide transport using PAMPA, Caco-2 and MDCKII-hMDR1 assays. Croat. Chem. Acta 83 (2010), 323–331.
117. [117] Pachot, J.I., Botham, R.P., Haegele, K.D., Hwang, K., Experimental estimation of the role of P-glycoprotein in the pharmacokinetic behaviour of telithromycin, a novel ketolide, in comparison with roxithromycin and other macrolides using the Caco-2 cell model. J. Pharm. Pharm. Sci. 6 (2003), 1–12.
118. [118] Padovan, J., Ralic, J., Letfus, V., Milic, A., Mihaljevic, V.B., Investigating the barriers to bioavailability of macrolide antibiotics in the rat. Eur. J. Drug Metab. Pharmacokinet. 37 (2012), 163–171.
119. [119] Ito, S., Nasu, R., Tsujimoto, M., Murakami, H., Ohtani, H., Sawada, Y., Effect of macrolide antibiotics on uptake of digoxin into rat liver. Biopharm. Drug Dispos. 28 (2007), 113–123.
120. [120] Tian, X., Li, J., Zamek-Gliszczynski, M.J., Bridges, A.S., Zhang, P., Patel, N.J., Raub, T.J., Pollack, G.M., Brouwer, K.L.R., Roles of P-glycoprotein, Bcrp, and Mrp2 in biliary excretion of spiramycin in mice. Antimicrob. Agents Chemother. 51 (2007), 3230–3234.
121. [121] Gertz, M., Harrison, A., Houston, J.B., Galetin, A., Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab. Dispos. 38 (2010), 1147–1158.
122. [122] Bilello, J.P., Dousson, C.B., Colla, M.L., Chapron, C., Bhadresa, S., Camire, M., Serra, I., Gillum, J.M., Lallos, L.B., McCarville, J.F., Pan-Zhou, X.-R., Cohen, M.L., Standring, D.N., Antiviral and preclinical profiles of HCV NS5A inhibitors IDX380 and IDX719. 18th International Symposium on Hepatitis C Virus and Related Viruses, Seattle, 2011.
123. [123] Bousquet, L., Roucairol, C., Hembury, A., Nevers, M.C., Creminon, C., Farinotti, R., Mabondzo, A., Comparison of ABC transporter modulation by Atazanavir in lymphocytes and human brain endothelial cells: ABC transporters are involved in the atazanavir-limited passage across an in vitro human model of the blood–brain barrier. AIDS Res. Hum. Retrovir. 24 (2008), 1147–1154.
124. [124] Kis, O., Zastre, J.A., Hoque, M.T., Walmsley, S.L., Bendayan, R., Role of drug efflux and uptake transporters in atazanavir intestinal permeability and drug–drug interactions. Pharm. Res. 30 (2013), 1050–1064.
125. [125] Perloff, E.S., Duan, S.X., Skolnik, P.R., Greenblatt, D.J., von Moltke, L.L., Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab. Dispos. 33 (2005), 764–770.
126. [126] Lamoureux, F., Picard, N., Boussera, B., Sauvage, F.-L., Marquet, P., Sirolimus and Everolimus intestinal absorption and interaction with calcineurin inhibitors: a differential effect between Cyclosporine and Tacrolimus. Fundam. Clin. Pharmacol. 26 (2012), 463–472.
127. [127] Pawarode, A., Shukla, S., Minderman, H., Fricke, S.M., Pinder, E.M., O'Loughlin, K.L., Ambudkar, S.V., Baer, M.R., Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins. Cancer Chemother. Pharmacol. 60 (2007), 179–188.
128. [128] Picard, N., Levoir, L., Lamoureux, F., Yee, S.W., Giacomini, K.M., Marquet, P., Interaction of sirolimus and everolimus with hepatic and intestinal organic anion-transporting polypeptide transporters. Xenobiotica 41 (2011), 752–757.
129. [129] Fahr, A., Cyclosporine clinical pharmacokinatics. Clin. Pharmacokinet. 24 (1993), 472–495.
130. [130] Hopkins, S., Scorneaux, B., Huang, Z., Murray, M.G., Wring, S., Smitley, C., Harris, R., Erdmann, F., Fischer, G., Ribeill, Y., SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro. Antimicrob. Agents Chemother. 54 (2010), 660–672.
131. [131] Ptachcinski, R.J., Burckart, G.J., Venkataramanan, R., Cyclosporine. Drug Intell. Clin. Pharm. 19 (1985), 90–100.
132. [132] Keogh, J.P., Kunta, J.R., Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein. Eur. J. Pharm. Sci. 27 (2006), 543–554.
133. [133] Li, Y., Theuretzbacher, U., Clancy, C.J., Nguyen, M.H., Derendorf, H., Pharmacokinetic/pharmacodynamic profile of posaconazole. Clin. Pharmacokinet. 49 (2010), 379–396.
134. [134] Ferlini, C., Gallo, D., Scambia, G., New taxanes in development. Expert Opin. Investig. Drugs 17 (2008), 335–347.
135. [135] Jing, Y.-r., Zhou, W., Li, W.-l., Zhao, L.-x., Wang, Y.-f., The synthesis of novel taxoids for oral administration. Bioorg. Med. Chem. 22 (2014), 194–203.
136. [136] Terwogt, J.M.M., Malingre, M.M., Beijnen, J.H., Huinink, W.W.T., Rosing, H., Koopman, F.J., van Tellingen, O., Swart, M., Schellens, J.H.M., Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin. Cancer Res. 5 (1999), 3379–3384.
137. [137] Cavet, M.E., West, M., Simmons, N.L., Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells. Br. J. Pharmacol. 118 (1996), 1389–1396.
138. [138] Polli, J.W., Wring, S.A., Humphreys, J.E., Huang, L.Y., Morgan, J.B., Webster, L.O., Serabjit-Singh, C.S., Rational use of in vitro P-glycoprotein assays in drug discovery. J. Pharmacol. Exp. Ther. 299 (2001), 620–628.
139. [139] Suhre, W.M., Ekins, S., Chang, C., Swaan, P.W., Wright, S.H., Molecular determinants of substrate/inhibitor binding to the human and rabbit renal organic cation transporters hOCT2 and rbOCT2. Mol. Pharmacol. 67 (2005), 1067–1077.
140. [140] Chang, C., Pang, K.S., Swaan, P.W., Ekins, S., Comparative pharmacophore modeling of organic anion transporting polypeptides: a meta-analysis of rat Oatp1a1 and human OATP1B1. J. Pharmacol. Exp. Ther. 314 (2005), 533–541.
141. [141] Montanari, F., Ecker, G.F., Prediction of drug-ABC-transporter interaction — recent advances and future challenges. Adv. Drug Deliv. Rev. 86 (2015), 17–26.
142. [142] Ekins, S., Kim, R.B., Leake, B.F., Dantzig, A.H., Schuetz, E.G., Lan, L.B., Yasuda, K., Shepard, R.L., Winter, M.A., Schuetz, J.D., Wikel, J.H., Wrighton, S.A., Application of three-dimensional quantitative structure–activity relationships of P-glycoprotein inhibitors and substrates. Mol. Pharm. 61 (2002), 974–981.
143. [143] Pearce, H.L., Safa, A.R., Bach, N.J., Winter, M.A., Cirtain, M.C., Beck, W.T., Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogues that modulate multidrug resistance. Proc. Natl. Acad. Sci. U. S. A. 86 (1989), 5128–5132.
144. [144] Hazai, E., Hazai, I., Ragueneau-Majlessi, I., Chung, S.P., Bikadi, Z., Mao, Q., Predicting substrates of the human breast cancer resistance protein using a support vector machine method. BMC Bioinf., 14, 2013.
145. [145] Pinto, M., Trauner, M., Ecker, G.F., An in silico classification model for putative ABCC2 substrates. Mol. Inf. 31 (2012), 547–553.
146. [146] Ferreira, R.J., Ferreira, M.-J.U., dos Santos, D.J.V.A., Insights on P-glycoprotein's efflux mechanism obtained by molecular dynamics simulations. J. Chem. Theory Comput. 8 (2012), 1853–1864.
147. [147] Huang, J., Ma, G., Muhammad, I., Cheng, Y., Identifying P-glycoprotein substrates using a support vector machine optimized by a particle swarm. J. Chem. Inf. Model. 47 (2007), 1638–1647.
148. [148] Jabeen, I., Wetwitayaklung, P., Klepsch, F., Parveen, Z., Chiba, P., Ecker, G.F., Probing the stereoselectivity of P-glycoprotein-synthesis, biological activity and ligand docking studies of a set of enantiopure benzopyrano[3,4-b][1,4]oxazines. Chem. Commun. 47 (2011), 2586–2588.
149. [149] Orlowski, S., Garrigos, M., Multiple recognition of various amphiphilic molecules by the multidrug resistance P-glycoprotein: molecular mechanisms and pharmacological consequences coming from functional interactions between various drugs. Anticancer Res. 19 (1999), 3109–3123.
150. [150] Pajeva, I.K., Globisch, C., Wiese, M., Structure-function relationships of multidrug resistance P-glycoprotein. J. Med. Chem. 47 (2004), 2523–2533.
151. [151] Poongavanam, V., Haider, N., Ecker, G.F., Fingerprint-based in silico models for the prediction of P-glycoprotein substrates and inhibitors. Bioorg. Med. Chem. 20 (2012), 5388–5395.
152. [152] Wang, Z., Chen, Y., Liang, H., Bender, A., Glen, R.C., Yan, A., P-glycoprotein substrate models using support vector machines based on a comprehensive data set. J. Chem. Inf. Model. 51 (2011), 1447–1456.
153. [153] Xue, Y., Yap, C.W., Sun, L.Z., Cao, Z.W., Wang, J.F., Chen, Y.Z., Prediction of P-glycoprotein substrates by a support vector machine approach. J. Chem. Inf. Comput. Sci. 44 (2004), 1497–1505.
154. [154] Garrigues, A., Loiseau, N., Delaforge, M., Ferte, J., Garrigos, M., Andre, F., Orlowski, S., Characterization of two pharmacophores on the multidrug transporter P-glycoprotein. Mol. Pharm. 62 (2002), 1288–1298.
155. [155] Raub, T.J., P-glycoprotein recognition of substrates and circumvention through rational drug design. Mol. Pharm. 3 (2006), 3–25.
156. [156] Seelig, A., A general pattern for substrate recognition by P-glycoprotein. Eur. J. Biochem. 251 (1998), 252–261.
157. [157] Seelig, A., How does P-glycoprotein recognize its substrates?. Int. J. Clin. Pharmacol. Ther. 36 (1998), 50–54.
158. [158] Li, D., Chen, L., Li, Y., Tian, S., Sun, H., Hou, T., ADMET evaluation in drug discovery. 13. Development of in silico prediction models for P-glycoprotein substrates. Mol. Pharm. 11 (2014), 716–726.
159. [159] Pajeva, I.K., Wiese, M., Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis). J. Med. Chem. 45 (2002), 5671–5686.
160. [160] Matsson, P., Bergstrom, C.A., Nagahara, N., Tavelin, S., Norinder, U., Artursson, P., Exploring the role of different drug transport routes in permeability screening. J. Med. Chem. 48 (2005), 604–613.
161. [161] Eytan, G.D., Mechanism of multidrug resistance in relation to passive membrane permeation. Biomed. Pharmacother. 59 (2005), 90–97.
162. [162] Kalvass, J.C., Pollack, G.M., Kinetic considerations for the quantitative assessment of efflux activity and inhibition: implications for understanding and predicting the effects of efflux inhibition. Pharm. Res. 24 (2007), 265–276.
163. [163] Desai, P.V., Raub, T.J., Blanco, M.-J., How hydrogen bonds impact P-glycoprotein transport and permeability. Bioorg. Med. Chem. Lett. 22 (2012), 6540–6548.
164. [164] Omote, H., Al-Shawi, M.K., Interaction of transported drugs with the lipid bilayer and P-glycoprotein through a solvation exchange mechanism. Biophys. J. 90 (2006), 4046–4059.
165. [165] Hann, M.M., Leach, A.R., Harper, G., Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Model. 41 (2001), 856–864.
166. [166] Hopkins, A.L., Mason, J.S., Overington, J.P., Can we rationally design promiscuous drugs?. Curr. Opin. Struct. Biol. 16 (2006), 127–136.